Building on a record year of Chromium product releases in 2024, 10x Genomics announced plans to enable high-performance, mega-scale single cell analysis with improved efficiency and ease of use.

10x Genomics Logo (PRNewsfoto/10x Genomics, Inc.) Interested parties may access a live webcast of the fireside chat on the "Investors" section of the company's website at: https://investors.

Morgan Stanley analyst Tejas Savant maintained a Buy rating on 10x Genomics (TXG – Research Report) today and set a price target of $26.00. The company’s shares closed yesterday at $11.94.

Biotech company 10x Genomics (NASDAQ:TXG) will be reporting earnings tomorrow after market hours. Here’s what to look for. 10x Genomics missed analysts’ revenue expectations by 5% last quarter ...

10x Genomics Price Performance Shares of TXG opened at $12.31 on Tuesday. The firm has a market cap of $1.49 billion, a PE ratio of -8.05 and a beta of 1.85. The stock’s fifty day moving average ...

PLEASANTON, Calif., Feb. 18, 2025 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that members of its management team will participate in ...

Leerink Partners lowered 10x Genomics from an “outperform” rating to a “market perform” rating and cut their price target for the stock from $25.00 to $12.00 in a research report on Thursday.

Leerink downgraded 10x Genomics (TXG) to Market Perform from Outperform with a price target of $12, down from $25. Despite having the market leading position in the single-cell market and a ...

10x Genomics posted a Q4 EPS loss of $(0.40), missing the $(0.30) estimate. The company’s 2025 sales guidance of $610M-$630M is below the $631.14M consensus. Get two weeks of free access to pro ...

Macroeconomic uncertainties could impact spending in academia and biopharma. 10x Genomics delivered strong Q4 2023 results with substantial contributions from Xenium and Visium platforms.

10X Genomics reported a Q4 2024 EPS of -$0.40, below the forecast of -$0.31. Revenue for the quarter was $165 million, exceeding expectations but down 10% year-over-year. The stock dropped 6.75% ...